Results 181 to 190 of about 747,960 (296)

Cannabidiol in Adults With Lennox–Gastaut Syndrome: Real‐World Experience

European Journal of Neurology, Volume 33, Issue 10, October 2026.
Cannabidiol showed sustained effectiveness and good tolerability in adults with LGS, with high retention over a median follow‐up of 41 months. Treatment was associated with improvement in seizure burden, increased seizure‐free days, fewer seizure‐related hospital admissions, and caregiver‐reported improvement in cognitive and behavioural functioning ...
Pyae Aung, Debbie Miller, Emily Sewell, Laura Mantoan Ritter, Evangelia Theochari, Ioannis Stavropoulos, Robert Delamont, Mark P. Richardson, Joel S. Winston, Lina Nashef   +9 more
wiley   +1 more source

Use of Wearable Sensors in Angelman Syndrome: A Systematic Review

Journal of Intellectual Disability Research, Volume 70, Issue 10, Page 985-1000, October 2026.
ABSTRACT Background Wearable sensors are a promising method for collecting clinical trial outcome data for people with Angelman syndrome (AS). However, there has yet to be a systematic probe into the ways in which wearable sensors have been successfully used in AS. The current study aims to provide a quantitative summary of wearable sensors used in AS,
Veronika Vozka, Wei Siong Neo, Jane Kinkus Yatcilla, Carolyn E. B. McCormick, Roslyn Harold, Kimberly Gálvez‐Ortega, Mihir Dey, Laura E. Fitzpatrick, A. J. Schwichtenberg, Orlando S. Hoilett, Dan Foti, Bridgette L. Kelleher   +11 more
wiley   +1 more source

The Ketogenic Diet as Adjunctive Strategy in Cancer Treatment-Therapeutic Benefits and Metabolic Risk Using Breast Cancer as an Example. [PDF]

Nutrients
Szołtysek J, Szymańska B, Piwowar A.
europepmc   +1 more source

Fenofibrate Protects Against Antipsychotic‐Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
The proposed mechanism through which fenofibrate protects against olanzapine‐induced hyperglycemia in mice. ABSTRACT Antipsychotic (AP) medications, such as olanzapine, cause acute weight gain independent of hyperglycemia through a glucagon‐dependent mechanism.
Michael Akcan, Stewart Jeromson, Bradley J. Baranowski, Annalaura Bellucci, Serena Trang, Katelyn Eisner, Ailish Babicki‐Moore, Hadil Alfares, Meagan Arbeau, Kyle Medak, Margaret Hahn, David C. Wright   +11 more
wiley   +1 more source

Managing Drug-Resistant Epilepsy and Severe Feeding Difficulties in Miller-Dieker Syndrome: The Role of Enteral Ketogenic Diet. [PDF]

Case Rep Pediatr
Michela P, Matteo P, Pasqua P, Paola R, Silvana G, Monica F.   +5 more
europepmc   +1 more source

Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM

Annals of Clinical and Translational Neurology, Volume 13, Issue 9, Page 1759-1771, September 2026.
ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina, Anna Marcé‐Grau, Barbara Masotto, Marta Codina, Lamia BenJemaa, Yasmina Elaribi, Mónica Martinez‐Gallo, Roger Colobran, Angel Sanchez‐Montañez, Irene Valenzuela, Yoshiko Murakami, Alfons Macaya   +11 more
wiley   +1 more source

The impact of the ketogenic diet on the health of patients with metabolic syndrome: a scoping review. [PDF]

Front Nutr
Winiarska M, Wiśniewska D, Klimas M, Jucha D, Szczupak M, Kobak J, Krupa-Nurcek S.   +6 more
europepmc   +1 more source

Cross‐tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Apolipoprotein E (APOE) ε4 is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD), but its contribution to disease pathogenesis remains incompletely understood. METHODS Here, we integrate proteomic profiling of plasma (n = 9028), cerebrospinal fluid (n = 1099), dorsolateral prefrontal cortex (n = 720), and ...
Artur Shvetcov, Shannon Thomson, Mark E. Graham, Brittany Hauger, Jessica E. Keller, Christine J. Smoyer, Sarah E. Tague, Ann‐Na Cho, Farhad B. Imam, Varsha Krish, Global Neurodegeneration Proteomics Consortium (GNPC), Matthew K. Taylor, Jonathan D. Mahnken, Debra K. Sullivan, Joanne H. Reed, Jeffrey M. Burns, Chad Slawson, Russell H. Swerdlow, Heather M. Wilkins, Caitlin A. Finney   +19 more
wiley   +1 more source

International advocacy for ketogenic diet research in schizophrenia: insights from a public petition. [PDF]

Front Public Health
Murray SL, Roche DJO, Palmer CM, Chen S, Lee H, Vyas G, Adams HA, Harrington V, Kelly DL.   +8 more
europepmc   +1 more source

Gut–Brain Axis Modulation by Short‐Chain Fatty Acids Exerts Disease‐Modifying Effects in a Murine Model of Drug‐Resistant Epilepsy

Annals of Neurology, Volume 100, Issue 3, Page 613-627, September 2026.
Objective Drug‐resistant epilepsy (DRE) remains a clinical challenge, as therapies modifying disease trajectory are lacking. Increasing evidence implicates gut microbiota dysbiosis in epilepsy pathophysiology, with short‐chain fatty acids (SCFAs) emerging as key microbial metabolites with neuroprotective and anti‐inflammatory properties.
Akash A. Bera, Rossella Di Sapia, Greta Volpedo, Sneha Anand, Eray Sahin, Pasquale Baldassarre, Francesca Buffelli, Andrea Petretto, Chiara Lavarello, James D. Mills, Gabriele Cattaneo, Ilaria Craparotta, Eleonora Aronica, Antonella Riva, Pasquale Striano, Annamaria Vezzani, Teresa Ravizza   +16 more
wiley   +1 more source